Main clinical signs presented by Covid positive patients
Keywords:
Covid-19; Symptomatology; Infection; RevisionAbstract
In late December 2019, an outbreak of a mysterious viral pneumonia broke out in Wuhan, Hubei Province, People's Republic of China, in which the causative agent was identified as a new coronavirus provisionally named 2019-nCoV. The world is currently experiencing a severe pandemic caused by the infection officially called COVID-19, which occurs due to contamination by the SARS-CoV-2 virus. Despite the countless information about its symptoms, there is still a lack of scientific evidence. Therefore, this work is important to inform the general parameter of the symptomatology of the infection caused by the SARS-CoV-2 virus. The study in question refers to a review of the scientific literature based on the databases Scielo, Lilacs, Pubmed and Bireme; we searched for the descriptors COVID-19, viral infection, SARS-CoV-2. To carry out this study, a survey was carried out from June 2017 to March 2021, with the inclusion criteria of articles in Portuguese, English and Spanish, which met the requirements of the subject in question, in a clear and cohesive manner, published in reliable journals of recognized scientific rigor. Therefore, the general panorama of the symptoms of the infection caused by the SARS-CoV-2 virus was identified, in which milder symptoms were identified, the most frequent being fever, cough, dyspnea, myalgia and fatigue and severe illness usually presenting signs and symptoms of viral pneumonia that may progress to situations of Acute Respiratory Distress Syndrome (ARDS), acute heart failure, acute kidney injury, on infection, sepsis or shock.
Downloads
References
BERGER, Z.D. Covid-19: control measures must be equitable and inclusive. BMJ, p. 368, 2020.
CAO, W.; LI, T. COVID-19: toward sunder standing of pathogenesis. Cell Res, n. 30, p. 367–369, 2020.
CDC Covid- Response Team. Preliminary Estimates of the Prevalence of Selected Underlying Health Conditions Among Patients with Coronavirus Disease 2019 - United States, February 12-March 28, 2020. MMWR Morb Mortal Wkly Rep 69: 382-386, 2020.
CHEN, J. Pathogenicity and transmissibility of SARS-CoV-2 quick overview and comparison with other emerging viruses. Microbes and Infection, v.22 (2), p.69-71, 2020.
CHEN, N.; ZHOU, M.; DONG, X. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet, n.395 (10223), p.507-13, 2020.
DI MAURO, G.; CRISTINA, S.; CONCETTA, R.; FRANCESCO, R.; ANNALISA, C. -Cov-2 infection: Response of human immune system and possible implications for the rapid test and treatment. Int Immunopharmacol, v.84: 106519, 2020.
DU, Z.; XU, X.; WU, Y. Serial interval of COVID-19 among publicly reported confirmed cases. Emerg Infect Dis, n. 26 (6), 2020.
ELFIKY, A. A. Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study. Life Sciences, 2020.
General Office of National Health Commission; General Office of National Administration of Traditional Chinese Medicine. Diagnostic and treatment protocol for Novel Coronavirus Pneumonia; (Trial version 6). Disponível em : http://www.nhc.gov.cn/yzygj/s7653p/202002/8334a8326dd94d329df351d7da8aefc2.shtml. Acessado em: 05 de novembro de 2020.
GOMES, I. S.; CAMINHA, I. de O. Guia para estudos de revisão sistemática: uma opção metodológica para as Ciências do Movimento Humano. Movimento, Porto Alegre, v. 20, n. 1, p. 395-411, jan/mar. 2014.
HILGENFELD, R. From SARS to MERS: crystallo graphic studies on coronaviral proteases enable antiviral drug design, The FEBS journal, n.281 (18), p.4085-4096, 2017.
HUANG, C.; WANG, Y.; LI, X.; REN, L.; ZHAO, J.; HU, Y. et al. Características clínicas de pacientes infectados com novo coronavírus de 2019 em Wuhan, China. Lanceta, 2020.
ISER, B. P. M.; SILVA, I.; RAYMUNDO, V. T.; POLETO, M. B.; TREVISOL, F. S.; BOBINSKI, F. Definição de caso suspeito da COVID-19: uma revisão narrativa dos sinais e sintomas mais frequentes entre os casos confirmados. Epidemiol. Serv. Saúde. Brasília, n. 29(3), 2020.
JUN, Z. SARS-CoV-2: an Emerging Coronavirus that Causes a Global Threat. Int. Journal of Biological Sciences, v.16 (10), p.1678-1685, 2020.
KAMPF, G.; PFAENDER, S.; TODT, D.; STEINMANN, E. G. Persistence of coronaviruses oninanimate surfaces and their inactivation with biocidalagents. J Hosp Infect, v.104(3), p.246 a 251, 2020.
Ministério da Saúde. Boletim COE COVID-19. Centro de Operações de Emergência em Saúde Pública/Doença pelo coronavírus 2019, Boletim Epidemiológico 12 – COE COVID-19 – 19 de abril de 2020. Disponível em: https://portalarquivos.saude.gov.br/images/pdf/2020/April/19/BE12-Boletim-doCOE.pdf. Acessado em: 07 de novembro de 2020
Ministério da Saúde. Portaria N° 2.349 GM/MS, de 14 de setembro de 2017, aprova a publicação da Classificação de Risco dos Agentes Biológicos. Diário Oficial da União, Brasília, Publicado em: 22 de setembro de 2017, Edição 183, Seção 1 Página 51.
MORTY, R. E.; ZIEBUHR, J. The pathophysiology of COVID-19 and SARS-CoV-2 infection. American Journal of Physiology – Lung Cellular and Molecular Physiology, on April 27, 2020.
MUNSTER, V.J.; KOOPMANS, M.; DOREMALEN, N.V.; RIEL, D.V.; WIT, E. Um novo coronavírus emergindo na China - questões-chave para avaliação de impacto. N Engl J Med, 2020.
Organização Mundial da Saúde. Novel Coronavirus (2019-nCoV). Disponível em: https://www.who.int/emergencies/diseases/novel-coronavirus-2019. Acessado em 5 de novembro de 2020.
Organização Mundial da Saúde. Relatório da situação 2019-nCoV. Disponível em: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports /. Acessado em 5 de novembro de 2020.
PETROSILLO, N.; VICECONTE, G.; ERGONUL, O.; IPPOLITO, G.; PETERSEN, E. COVID-19, SARS and MERS: are they closely related? Clin Microbiol Infect, 2020.
SCHUTZ, G.R.; SANT'ANA, A. S. S.; SANTOS, G. S. da. Política de periódicos nacionais em Educação Física para estudos de revisão/sistemática. Revista Brasileira de Cineantropometria e Desempenho Humano (Online), Florianópolis, v. 13, n. 4, p. 313-319, ago, 2011.
SINGHAL, T. A review of coronavirus disease-2019 (COVID-19). Indian J Pediatr, n ,87, p.281-6, 2020.
VAN DOREMALEN, N.; BUSHMAKER, T.; MORRIS D.H., Et al. Aerosol and Surface Stabilityof SARS-CoV-2 as Compared with SARS-CoV-1. N Engl J Med, v.382(16), p.1564 a 1567, 2020.
WANG, Q. Structural and functional basis of SARS-CoV-2 entry by using human ACE2. Cell, ed. 9, n.181, p. 894–904, 2020.
WRAPP, D.Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science, n.367, p.1260–126, 2020.
World Health Organization: Laboratory biosafety guidance related to coronavirus disease 2019 (COVID-19). WHO, 2020. Disponível em: https://apps.who.int/iris/bitstream/handle/10665/331138/WHO-WPE-GIH-2020.1-eng.pdf. Acessado em: 06 de novembro de 2020.
YAN, C.H.; FARAJI, F.; PRAJAPATI, D. P.; BOONE, C. E.; DE CONDE, A. S. Association of chemosensorydys function and Covid 19 in patients presenting with influenza?like symptoms. Int Forum Allergy Rhinol, 2020.
ZAKI, A. M.; VAN BOHEEMEN, S.; BESTEBROER, T. M.; OSTERHAUS, T. M.; OSTERHAUS, A. D.; FOUCHIER, R. A. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med, n.367, p.1814-1820, 2012.
ZHU, N.; ZHANG, D.; WANG, W.; LI, X.; YANG, B.; SONG, J.; ZHAO, X.; HUANG, B.; SHI, W.; LU, R.; NIU, P.; ZHAN, F.; MA, X.; WANG, D.; XU, W.; XU, G.; GAO, G. F.; TAN, W. China Novel Coronavirus Investigating and Research Team: A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med, n. 382, p. 727-733, 2020.